Drug Profile
NYK 1001
Alternative Names: NNYK-1001; NYK-1001Latest Information Update: 17 Mar 2017
Price :
$50
*
At a glance
- Originator Nyken
- Class Antiarrhythmics
- Mechanism of Action Heat-shock protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Atrial fibrillation
Most Recent Events
- 11 Jan 2011 NYK 1001 is available for licensing as of 11 Jan 2011. http://www.nyken.com